0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessWe aimed to investigate the causal effect of circulating uric acid concentrations on type 2 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 uric acid-associated loci. We used data of the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, comprising 24,265 individuals of European ancestry from eight European countries. During a mean (SD) follow-up of 10 (4) years, 10,576 verified incident case subjects with type 2 diabetes were ascertained. Higher uric acid was associated with a higher diabetes risk after adjustment for confounders, with a hazard ratio (HR) of 1.20 (95% CI 1.11, 1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic score raised uric acid by 17 µmol/L (95% CI 15, 18) per SD increase and explained 4% of uric acid variation. By using the genetic score to estimate the unconfounded effect, we found that a 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 1.01 [95% CI 0.87, 1.16]). Including data from the Diabetes Genetics Replication And Meta-analysis (DIAGRAM) consortium, increasing our dataset to 41,508 case subjects with diabetes, the summary odds ratio estimate was 0.99 (95% CI 0.92, 1.06). In conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk. Uric acid-lowering therapies may therefore not be beneficial in reducing diabetes risk.
Ivonne Sluijs, Michael V. Holmes, Yvonne T. van der Schouw, Joline W. J. Beulens, Folkert W. Asselbergs, José María Huerta, Tom Palmer, Larraitz Arriola, Beverley Balkau, Aurelio Barricarte, Heiner Boeing, Françoise Clavel‐Chapelon, Guy Fagherazzi, Paul W. Franks, Diana Gavrila, Rudolf Kaaks, Kay‐Tee Khaw, Tilman Kühn, Esther Molina‐Montes, Lotte Maxild Mortensen, Peter M. Nilsson, Kim Overvad, Domenico Palli, Salvatore Panico, J. Ramón Quirós, Olov Rolandsson, Carlotta Sacerdote, Núria Sala, Julie A. Schmidt, Robert A. Scott, Sabina Sieri, Nadia Slimani, Annemieke M. W. Spijkerman, Anne Tjønneland, Ruth C. Travis, Rosario Tumino, Daphne L. van der A, Stephen J. Sharp, Nita G. Forouhi, Claudia Langenberg, Elio Riboli, Nicholas J. Wareham (2015). A Mendelian Randomization Study of Circulating Uric Acid and Type 2 Diabetes. , 64(8), DOI: https://doi.org/10.2337/db14-0742.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2015
Authors
42
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.2337/db14-0742
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
